Therapeutic benefit of Ac-225 labeled anti-CD33 monoclonal antibody was evaluated in a phase-1 clinical trial in acute myeloid leukemia (AML) patients where median progression free survival (PFS) and median overall survival of 2.7 months and 5.5 months respectively were observed [44, 45]. Here, CD33 is linked to acute myeloid leukemia.